Relay Therapeutics, Inc.
RLAYNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RLAY. That does not mean none is planned.
Get an email about RLAY's next catalysts
Track Relay Therapeutics (RLAY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
RLAY Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.40 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
RLY-2608
PIK3CA Mutation
Zovegalisib
PIK3CA Mutation
RLY-8161
Advanced NRAS-Mutant Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RLY-2608 | Phase 3 | PIK3CA Mutation | - | - |
Zovegalisib | Phase 3 | PIK3CA Mutation | - | - |
RLY-8161 | Phase 2 | Advanced NRAS-Mutant Melanoma | - | - |
PIK3CA Mutation
1 drug in this indication
PIK3CA-Related Overgrowth Spectrum (PROS)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Relay Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Relay Therapeutics, Inc.'s (RLAY) pipeline across Phase 3, Phase 2. Its lead program is RLY-2608 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Relay Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Relay Therapeutics, Inc. (RLAY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RLAY biotech catalysts?→
Add RLAY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Relay Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.